Breaking News, Trials & Filings

AgeneBio Publishes Phase 2 Results for Delaying Onset of Alzheimer’s

First and only clinical trial to reduce hippocampal overactivity during aMCI, the pre-dementia stage of Alzheimer’s disease

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling amnestic mild cognitive impairment (aMCI), the pre-dementia stage of Alzheimer’s disease, and other neurological and psychiatric diseases, has published complete Phase 2 clinical trial results in NeuroImage: Clinical for its lead product candidate. According to the company, results show that AGB101 restored brain network function and significantly improved memory in elderly patients with aMCI. Th...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters